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The transmembrane subunit (gp41) of the HIV Env glycoprotein contains conserved neutralizing epitopes which are not well-exposed in wild-
type HIV Env proteins. To enhance the exposure of these epitopes, a chimeric protein, HA/gp41, in which the gp41 of HIV-1 89.6 envelope
protein was fused to the C-terminus of the HA1 subunit of the influenza HA protein, was constructed. Characterization of protein expression
showed that the HA/gp41 chimeric proteins were expressed on cell surfaces and formed trimeric oligomers, as found in the HIV Env as well as
influenza HA proteins. In addition, the HA/gp41 chimeric protein expressed on the cell surface can also be cleaved into 2 subunits by trypsin
treatment, similar to the influenza HA. Moreover, the HA/gp41 chimeric protein was found to maintain a pre-fusion conformation. Interestingly,
the HA/gp41 chimeric proteins on cell surfaces exhibited increased reactivity to monoclonal antibodies against the HIV Env gp41 subunit
compared with the HIV-1 envelope protein, including the two broadly neutralizing monoclonal antibodies 2F5 and 4E10. Immunization of mice
with a DNA vaccine expressing the HA/gp41 chimeric protein induced antibodies against the HIV gp41 protein and these antibodies exhibit
neutralizing activity against infection by an HIV SF162 pseudovirus. These results demonstrate that the construction of such chimeric proteins can
provide enhanced exposure of conserved epitopes in the HIV Env gp41 and may represent a novel vaccine design strategy for inducing broadly
neutralizing antibodies against HIV.
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A vaccine for prevention of HIV infection is likely to
require effective humoral as well as cellular immune res-
ponses (Nabel, 2001). This is demonstrated by the observa-
tions that although a strong CTL immune response can
control virus replication and disease progression in immu-
nized macaques, it fails to confer protection from virus infec-
tion (Amara et al., 2001; Barouch et al., 2001). On the other
hand, recent studies have shown that neutralizing antibodies
against HIV can prevent infection in primates and accelerate⁎ Corresponding author. Fax: +1 404 727 3659.
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doi:10.1016/j.virol.2006.04.012clearance of cell-free virions from the blood of monkeys
(Igarashi et al., 1999; Shibata et al., 1999). Furthermore,
infusion of human neutralizing monoclonal antibodies to
monkeys intravenously can protect adult as well as neonatal
monkeys from mucosal infection by a simian–human
immunodeficiency virus (Baba et al., 2000; Mascola et al.,
2000; Parren et al., 2001). These studies support the idea that
vaccines inducing strong neutralizing antibodies against
primary isolates of different subtypes may be effective in
the prevention of HIV-1 infection. However, the develop-
ment of HIV vaccines to elicit cross-reactive neutralizing
antibody responses remains a difficult task for the research
community.
The human immunodeficiency virus (HIV) envelope
protein mediates virus infection of the cell and is also the
75L. Ye et al. / Virology 352 (2006) 74–85target for neutralizing antibodies of the host immune
response. It is synthesized as a precursor (gp160), which is
subsequently processed by a cellular protease into two non-
covalently associated subunits, a surface subunit (gp120) and
a transmembrane subunit (gp41) (Allan et al., 1985;
Hallenberger et al., 1992). The envelope (Env) protein exists
on the cell surface or the surface of the virion in the form of a
trimer comprised of the gp120/gp41 heterodimers (Wyatt and
Sodroski, 1998). The surface subunit gp120 is responsible for
binding to the receptor and coreceptor molecules on the cell
surface, whereas the transmembrane subunit gp41 contains a
hydrophobic fusion peptide at its N-terminus and mediates
fusion between viral and cellular membranes and virus entry
into the cell (Chan and Kim, 1998). The gp120 subunit is
heavily glycosylated and contains five hypervariable regions
that mask neutralizing epitopes and mediate virus escape from
neutralizing antibodies (Wyatt et al., 1998). In contrast, the
gp41 subunit is relatively conserved. Structural and functional
studies show that gp41 exists in two conformations, a native
conformation and a fusion active conformation. Upon binding
to its cellular receptor and coreceptor molecules, the native
envelope protein trimer undergoes a series of conformational
changes, which lead to the adoption of the fusion-active state
and the formation of a six-helix bundle structure (Chan et al.,
1997).
The HIV-1 Env gp41 serves to anchor the protein to cellular
and viral membranes and mediate membrane fusion during
virus entry into the cell. Although most of gp41 appears to be
completely occluded in the HIV-1 envelope spike, recentFig. 1. (A) Schematic diagram of influenza HA, HIV89.6 EnvTr, and the HA/gp41 c
in the HA/gp41 chimeric protein is shown and the underlined amino acids are from H
cell. HeLa cells were infected with VTF7-3 and transfected with plasmid DNA con
against HA, HIV, and the monoclonal antibody 2F5 against HIV gp41. Lane 1
transfection with plasmid DNA construct expressing HA; lane 3, transfection with p
or HA/gp41 proteins.studies indicate that regions of gp41 close to the transmem-
brane domain are accessible to neutralizing antibodies and can
be a promising target for vaccine design (Zwick, 2005).
Several mAbs (2F5, Z13, 4E10), which neutralize a broad
range of primary HIV-1 isolates, are known to bind to the
extracellular domain of gp41 at its membrane-proximal region
(Muster et al., 1993; Stiegler et al., 2001; Zwick et al., 2001).
However, effort to design HIV vaccines for eliciting broadly
neutralizing antibodies directed against these conserved
epitopes has met little success (Moore et al., 2001). One
possible reason for the difficulty in eliciting neutralizing
antibodies against these conserved epitopes may be the lack of
exposure of these epitopes to the immune system. This is
supported by studies of the structure of the HIV-1 envelope
protein (Kwong et al., 1998; Wyatt et al., 1998), which show
that conserved epitopes are either hidden behind variable loops
or are obscured by carbohydrates. Therefore, the design of
novel proteins that can present these conserved neutralizing
epitopes in gp41 more efficiently may lead to the development
of HIV vaccines that are more effective in eliciting broadly
neutralizing antibodies.
Structural studies have indicated that the HIV Env gp41
forms structures similar to the HA2 subunit of the influenza
HA protein (Colman and Lawrence, 2003). In this study,
based on the structural similarity between HIV-1 gp41 and
influenza HA2, we constructed a chimeric protein HA/gp41 in
which the HA2 subunit in the influenza HA protein is
replaced by the HIV 89.6 gp41 and analyzed its surface
expression and reactivity to monoclonal antibodies againsthimeric protein. The amino acid sequence at the junction of HA1 and HIV gp41
A1. (B) Western blot analysis of HA/gp41 and influenza HA expression in the
structs as described in the text and protein expression was detected by antisera
, mock transfection with plasmid vector pBlueScript IIKS (control); lane 2,
lasmid DNA construct expressing HA/gp41. Arrows indicate the bands for HA
Fig. 2. Expression of influenza HA and the HA/gp41 chimeric protein on the
cell surface. Expression of HA and HA/gp41 were carried out by infection
and transfection of HeLa cells as described in the text. Surface expression of
the HA/gp41 chimeric protein was analyzed in comparison with HA by
radioactive labeling followed by surface biotinylation and immunoprecipita-
tion using antibodies against HA. Lane 1, mock transfection control; lane 2,
influenza HA; lane 3, HA/gp41. Arrows indicate the bands for HA or HA/
gp41 proteins.
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efficiently transported to the cell surface and exhibits
enhanced exposure of the highly conserved neutralizing
epitopes recognized by the monoclonal antibodies against
HIV gp41.
Results
Construction and expression of the HA/gp41 chimeric protein
As depicted in Fig. 1, we constructed a chimeric protein
containing the HA1 subunit and the HIV Env protein
transmembrane subunit gp41. The amino acid sequence at
the junction of the HA/gp41 chimeric protein is also shown
in Fig. 1. The rationale for construction of such a chimeric
protein is to replace the large, highly glycosylated surfaceFig. 3. The HA/gp41 chimeric protein forms oligomers. Protein expression was car
Radioactive labeling and immunoprecipitation were carried out as described in Ma
reducing or non-reducing sample buffers as indicated in the figure, and then resolved b
gp41; lane 4, HIV89.6 EnvTr. Arrows indicate the monomers, dimers, and trimers ounit gp120 of the HIV Env protein with the relatively
smaller subunit HA1, with the aim to enhance exposure of
conserved epitopes in the HIV Env transmembrane subunit
gp41.
To determine whether the chimeric protein can be stably
expressed in the cell, we employed the vaccinia virus T7
expression system and analyzed protein expression by Western
blot using primary antibodies against the HIV Env as well as
influenza HA proteins. As shown in Fig. 1B, both the influenza
HA and the chimeric protein HA/gp41 were expressed in the
cells and there is no significant difference in their levels of
expression when detected with antibodies against the HA.
Moreover, the HA/gp41 chimeric protein was also recognized
by polyclonal antibodies (HIVIG) against HIV-1 as well as the
monoclonal antibody 2F5 against HIV Env gp41. These results
show that the HA/gp41 chimeric protein is stably expressed in
the cells.
The HA/gp41 chimeric protein is expressed on the cell surface
One of the critical issues in construction of such a chimeric
glycoprotein is whether after synthesis it will be correctly folded
and transported to the cell surface. Previous studies have shown
that misfolded HIV Env or influenza HA proteins were not
transported to the cell surface. Instead, they were found to be
retained intracellularly after synthesis and then degraded in the
lysosomes of the cell (Chao, 1992; Willey et al., 1988). To
determine whether the HA/gp41 chimeric protein is transported
to the cell surface, we employed radioactive labeling coupled
with surface biotinylation and immunoprecipitation (Yang and
Compans, 1996). As shown in Fig. 2, the HA/gp41 chimeric
protein was found to be expressed at comparable levels to the
influenza HA both in the cell and on the cell surface. These
results showed that the HA/gp41 chimeric protein was
efficiently transported to the cell surface after synthesis,
indicating that the chimeric protein is folded into a transport-
competent form.ried out in HeLa cells using the vaccinia virus T7 transient expression system.
terials and methods. Protein samples were split into two parts and mixed with
y 3.5% SDS–PAGE. Lane 1, mock transfection control; lane 2, HA; lane 3, HA/
f the HA or HA/gp41 proteins.
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and can be cleaved by treatment with trypsin
One important issue for the design and construction of
chimeric proteins is whether such chimeric proteins will
oligomerize properly when expressed. Previous studies have
shown that both influenza HA and HIV Env proteins form
trimers. To investigate whether the HA/gp41 chimeric protein
retain the ability to form trimers, we compared the oligomer-
ization property of the HA/gp41 chimeric protein with influenza
HA and HIV 89.6 Env proteins by analysis with non-reducing
SDS–PAGE. As shown in Fig. 3, oligomers in the forms of
dimer and trimer were readily detected for the HA/gp41
chimeric protein as observed for the influenza HA and the HIV
Env proteins, indicating that the HA/gp41 chimeric protein was
properly oligomerized after synthesis.
In addition, both the influenza HA and the HIV Env
glycoproteins are synthesized as a precursor protein, which is
then cleaved into two subunits. As shown in Fig. 1A, the HA/
gp41 chimeric protein, which is comprised of the HA1 subunit
of the influenza HA protein and the gp41 subunit of the HIVFig. 4. Cleavage of the HA/gp41 chimeric protein on cell surface by trypsin. Protein
expression system. At 16 h post-infection, the cells were washed twice with PBS and
at 37 °C. The cells were then lysed and cell lysates were added with reducing prote
antibodies against influenza HA and HIV Env gp41 (2F5), respectively. Lane 1, mo
Arrows indicate the bands for HA or HA/gp41 proteins as well as their cleavage prEnv protein, contains the protease cleavage site of HA that is not
cleaved in mammalian cells but can be cleaved by treatment
with trypsin. Consequently, as shown in Figs. 1 and 2, the HA/
gp41 chimeric protein was not cleaved when expressed in the
cell. We examined the cleavage processing of the HA/gp41
chimeric protein by trypsin treatment in comparison with the
influenza HA. As shown in Fig. 4, the HA/gp41 chimeric
protein is cleaved by trypsin treatment into two subunits, HA1
and gp41 (with a truncated cytoplasmic domain), as detected by
antibodies against HA or the monoclonal antibody 2F5 against
gp41, respectively. This is similar to the effect of trypsin
treatment on the influenza HA, which is cleaved into the HA1
and HA2 subunits, indicating that the cleavage site in the HA/
gp41 chimeric protein is accessible to trypsin treatment.
The HA/gp41 chimeric protein does not form a six-helix bundle
structure
The results from the above studies show that the HA/gp41
chimeric protein is efficiently transported to the cell surfaces
and forms trimers similarly as observed for the wild-type HIVexpression was carried out in HeLa cells using the vaccinia virus T7 transient
then treated with trypsin (5 μg/ml in PBS) or mock treatment with PBS for 5 min
in sample buffer and analyzed by SDS–PAGE followed by Western blot using
ck transfection control; lane 2, HA; lane 3, HA/gp41; lane 4, HIV89.6 EnvTr.
oducts.
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HA/gp41 chimeric protein may assume a post-fusion confor-
mation, which is characterized by the presence of a six-helix
bundle structure. It has been suggested that such a six-helix
bundle structure is ineffective in eliciting neutralizing anti-
bodies against HIV Env gp41 (Moore et al., 2001). To address
this possibility, we examined the reactivity of the HA/gp41
chimeric protein to a monoclonal antibody NC-1 that is specific
for HIV gp41 in a six-helix bundle structure (Jiang et al., 1998).
As shown in Fig. 5, both HA/gp41 and HA exhibited similar
reactivity to the antibody against influenza HA, but neither
interacted with the monoclonal antibody NC-1 as determined by
ELISA. To validate the effectiveness of the NC-1 monoclonal
antibody in such an assay, we constructed a chimeric protein
HN/gp41 in which the N-terminal 72 amino acids of the SV5
HN protein was fused to the N-terminus of the HIV gp41
protein. The HN/gp41 chimeric protein was expressed at high
levels intracellularly but failed to be transported to the cell
surface (data not shown). As also shown in Fig. 5, the NC-1
monoclonal antibody interacted with the HN/gp41 chimeric
protein in ELISA, confirming the reactivity of the NC-1
monoclonal antibody to the HIV gp41 six-helix bundle structureFig. 5. The HA/gp41 chimeric does not react with the monoclonal antibody NC-
1 that is specific for the post-fusion six-helix bundle structure of gp41. HA, HA/
gp41, and HIV89.6 EnvTr were expressed in HeLa cells by transfection. Cells
transfected with the plasmid vector pBlueScript IIKS (pBlue) were used as
controls. At 48 h post-transfection, the cells were lysed with lysis buffer and cell
lysates were directly coated onto a microtiter plate, followed by detection with
antibodies against HA or the monoclonal antibody NC-1, which is specific for
the HIV gp41 six-helix structure. Relative amounts of the antibody bound to the
cell lysates were expressed by the OD values for the wells at the wavelength of
450 nm. The average OD values from the wells expressing each protein and
binding to each antibody are shown.formed in a chimeric molecule under the assay conditions.
These results indicate that the HA/gp41 chimeric protein does
not assume the post-fusion six-helix bundle conformation when
expressed in the cell.
The HA/gp41 chimeric protein exhibits enhanced reactivity to
monoclonal antibodies against HIV gp41, including broadly
neutralizing antibodies 2F5 and 4E10
The above results showed that the HA/gp41 chimeric is
efficiently transported to the cell surfaces. To investigate
whether the design of the HA/gp41 chimeric protein provides
better exposure of the conserved neutralizing epitopes in the
HIV gp41 protein, as depicted in Fig. 1B, we examined the
interaction between the chimeric HA/gp41 on the cell surfaces
with several monoclonal antibodies against HIV Env gp41,
including the two broadly neutralizing monoclonal antibodies
2F5 and 4E10 as well as a non-neutralizing antibody 5F3, in
comparison with HIV Env and influenza HA. We also included
the monoclonal antibody 2G12 against HIV gp120 as well as
polyclonal antibodies against HIV and influenza HA for
comparison.
We first analyzed interaction between the HA/gp41 chimeric
protein and influenza HA and the HIV Env proteins expressed
on the cell surfaces with different antibodies by fluorescence
staining followed by flow cytometry. As shown in Fig. 6,
similar percentages of HA/gp41 expressing cells were stained
positively with all of the different antibodies except for 2G12,
which is specific for HIV Env gp120. On the other hand,
whereas the percentages of fluorescence-positive cells expres-
sing HIV 89.6 Env were about 2.44 and 2.89 as stained by
polyclonal antibodies against HIV (HIVIG) and 2G12,
respectively, the percentages of the HIV 89.6 Env expressing
cells that exhibit fluorescence above background levels are
much smaller when stained with monoclonal antibodies against
HIV Env gp41 (0.88% for 2F5, 0.93% for 4E10, and 0.19% for
5F3, respectively). As expected, cells expressing the HA were
negative for staining with HIV Env-specific antibodies whereas
cells expressing HIV 89.6 Env were negative for staining with
antibodies against influenza HA. These results indicate that the
antibody recognition sites in gp41, including the two broadly
neutralizing epitopes, are masked by the gp120 subunit in the
HIV Env protein, whereas these epitopes are more efficiently
exposed in the HA/gp41 chimeric protein and exhibit enhanced
reactivity to the corresponding monoclonal antibodies.
We further compared the reactivity of the HA/gp41 chimeric
protein and influenza HA and HIV Env proteins expressed on
cell surfaces with different antibodies by using cell surface
ELISA, which allows for comparison of the amount of total
antibodies bound to cell surface glycoproteins (Martin et al.,
1998). As shown in Fig. 7, significant levels of the monoclonal
antibodies 5F3, 2F5, and 4E10 against gp41 but not the
monoclonal antibody 2G12 against gp120 were found to bind to
the surface of cells expressing the HA/gp41 chimeric protein.
On the other hand, although significant levels of the monoclonal
antibody 2G12 were found to bind to the surface of HIV Env
expressing cells, the levels of 2F5 and 4E10 bound to the
Fig. 6. Surface HA/gp41 exhibits enhanced reactivity to the monoclonal antibodies against the HIV Env gp41 in comparison to the HIV89.6 EnvTr. Protein expression was carried out by infection and transfection of
HeLa cells seeded in T-75 flasks with DNA constructs as indicated on the left. Protein surface expression was probed using antibodies against HA, anti-HIV-1 sera (HIVIG), monoclonal antibodies against HIV Env gp41
(2F5, 4E10, and 5F3), or the monoclonal antibody against HIV Env gp120 (2G12), followed by incubation with FITC (goat anti-rabbit for anti-HA sera and goat anti-human for antibodies against HIV Env) conjugated
secondary antibodies. Events (20,000) were collected for each sample and data were analyzed using Flowjo 4.2 software. Percentage of cells stained positive for surface expression (lower right) is shown in the box.
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Fig. 7. Quantitative comparison of antibody binding to cell surface HA, fsHA/gp41, and the HIV89.6 EnvTr by cell surface ELISA. HA, HA/gp41, and HIV89.6
EnvTr were expressed in HeLa cells seeded in a 96-well plate by transfection and the reactivity of proteins expressed on cell surfaces to antibodies against HA or HIV
Env as indicated in each graph was determined as described in Materials and methods. Cells transfected with the plasmid vector pBlueScript IIKS (pBlue) were used as
controls. Relative amounts of the antibody bound to the cell surfaces were expressed by the average OD values from the wells expressing each protein and binding to
each antibody.
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than those bound to the surface of cells expressing the influenza
HA or control cells transfected by the plasmid vector pBlue-
script. Furthermore, the monoclonal antibody 5F3 against gp41
did not bind to the surfaces of HIV Env expressing cells.
Similarly as observed in surface fluorescence staining and flow
cytometry studies, antibodies against HAwere found to bind to
the surface of cells expressing the influenza HA as well as the
HA/gp41 chimeric protein but not the HIV Env protein. The
polyclonal antibodies against HIV (HIVIG) produced high
levels of background in cell surface ELISA (data not shown).
These results are in agreement with the results obtained by
surface fluorescence staining and flow cytometry analysis,
showing that the HA/gp41 chimeric protein expressed on thecell surface exhibits enhanced reactivity with monoclonal
antibodies against HIV Env gp41 compared to the wild-type
HIV Env protein.
Immunization with a DNA vaccine expressing the HA/gp41
chimeric protein induced antibody responses against the HIV
gp41 protein
To investigate the ability of the HA/gp41 chimeric protein to
induce antibodies against the HIV gp41 protein, we carried out
immunization studies in mice with a DNA vaccine expressing
the HA/gp41 chimeric protein. Balb/c mice (groups of 6) were
immunized three times with pCAGGS-HA/gp41 or the empty
plasmid vector pCAGGS (Control) at 4-week intervals and
81L. Ye et al. / Virology 352 (2006) 74–85blood samples were collected at 1 week prior to immunization
and 3 weeks after the final immunization. As shown in Fig. 8A,
significant levels of antibody response against the HIV gp41
were induced in all mice immunized with pCAGGS-HA/gp41
with endpoint titers ranging from 1:2000 to over 1:20000,
whereas no significant level of antibody response against gp41
was induced in mice immunized with the pCAGGS plasmid
vector even at the starting 1:500 dilution. Moreover, sera from
pCAGGS-HA/gp41 immunized mice were able to neutralize
HIV SF162 pseudoviruses albeit at low levels (about 40%
neutralization at 1:40 dilutions over group-matched pre-
immune sera). These results show that the HA/gp41 DNA
vaccine is able to induce a strong antibody response against the
HIV gp41 protein (antibody titers in 4 out 6 mice were over
1:10000) and these antibodies exhibit neutralizing activity
against HIV infection, further demonstrating the potential of the
chimeric HA/gp41 vaccine strategy.Fig. 8. (A) Antibody responses induced by DNA immunization with pCAGGS-
HA/gp41. Sera from mice immunized with pCAGGS-HA/gp41 or the plasmid
vector pCAGGS (Control) were collected at 1 week prior to immunization and
3 weeks after the third immunization and analyzed for antibodies specific for the
HIV gp41 protein by ELISA as described in Materials and methods. The levels
of antibody responses are expressed as the endpoint dilutions at which their
absorbance values (OD) are at least 0.05 U above the mean OD of the group-
matched pre-immune sera at the same dilution. Endpoint titers for sera from
individual mouse of each group were shown. (B) Neutralization of HIV SF162
pseudovirus by sera from immunized mice. Serial dilutions of pooled sera from
each immunization group were mixed with HIV SF162 pseudoviruses in
triplicates and neutralization of HIV SF162 was analyzed in JC53-BL cells as
described in Materials and methods. Neutralization was calculated as the
average percentage of plaque number reduction in comparison with mixing HIV
SF162 pseudoviruses with group-matched pre-immune sera at the same dilution.Discussion
In this study, we constructed an HA/gp41 chimeric protein
by fusing the sequence of the HIV 89.6 gp41 protein in frame
to the C-terminus of the HA1 subunit of the influenza virus A/
Aichi/2/68 HA protein. Analysis of protein expression by
Western blot showed that the chimeric protein is stably
expressed in the cell. Furthermore, the HA/gp41 chimeric
protein is efficiently transported to the cell surface and forms
trimers similar to those formed by the wild-type influenza HA
and HIV Env proteins. Moreover, the HA/gp41 chimeric
protein on the cell surface exhibits enhanced reactivity to
monoclonal antibodies against the HIV gp41, including two
broadly neutralizing antibodies that recognize conserved
epitopes located proximal to the transmembrane domain of
gp41. The HA/gp41 chimeric protein was found to retain the
pre-fusion conformation, which may present the epitopes in
HIV gp41 more effectively for eliciting neutralizing anti-
bodies. In addition, immunization with a DNA vaccine
expressing the HA/gp41 chimeric protein induced strong
antibody responses against the HIV gp41 protein and these
antibodies were able to neutralize infection by HIV SF162
pseudoviruses. These results indicate that the design of such
chimeric proteins to enhance the exposure of conserved
epitopes located in the membrane-proximal stem region of
the HIV Env protein gp41 extracellular domain may represent
a novel vaccine development approach for inducing broadly
neutralizing antibodies against HIV.
Many viral glycoproteins are type I transmembrane
proteins and they share common structural features such as
oligomerization and processing by protease cleavage into two
subunits during transport to the cell surface. Evidence
suggests that the three distinctive structural domains of type
I transmembrane proteins, that is, the extracellular domain,
transmembrane domain, and the cytoplasmic domain, are able
to properly fold independently of each other (Doms et al.,
1993). This property of the type I transmembrane proteins has
been exploited for construction of chimeric proteins with
replacement of transmembrane or cytoplasmic domains to
investigate specific functions of the different domains
(Browne et al., 2003; Ghosh and Ghosh, 1999; Jin and
Wright, 2003; Oeffner et al., 1999; Popova and Zhang, 2002).
Moreover, chimeric proteins have also been generated by
introducing a segment from one glycoprotein into the
extracellular domain of another glycoprotein for structural
and functional studies (Boomer et al., 1997; Cormier and
Dragic, 2002; Han et al., 1998; Lin et al., 2003; Si et al.,
2004; Tanabayashi and Compans, 1996). Notably, chimeric
influenza HA proteins containing large foreign sequences
inserted at its N-terminal or with insertion of the HIV gp41
2F5 epitope have been successfully generated and shown to
be expressed on cell surfaces (Hatziioannou et al., 1999;
Muster et al., 1995). However, our results show for the first
time that a chimeric protein, which is generated by replacing
an entire surface subunit of one viral glycoprotein with the
surface subunit of another viral glycoprotein, remains
competent to be transported to the cell surface and properly
82 L. Ye et al. / Virology 352 (2006) 74–85oligomerized. This is in contrast to early studies from our
laboratory, which showed that chimeric proteins between
influenza HA and vesicular stomatitis virus (VSV) G proteins
were not transported to the cell surface when portions of the
extracellular domains were exchanged, whereas the replace-
ment of the cytoplasmic domain or the transmembrane
domain did not affect the transport of the chimeric proteins
to the cell surface (McQueen et al., 1986). These observed
differences are probably due to the design of chimeric
proteins. In previous studies, the chimeric proteins were
constructed by exchanging parts of the surface subunit or the
transmembrane subunit between influenza HA and VSV G
proteins, whereas the HA/gp41 chimeric protein in the current
studies was constructed by precisely fusing the surface
subunit of influenza HA to the transmembrane subunit of
the HIV Env protein. It is interesting to note that the HA/gp41
chimeric protein expressed on the cell surface also retained
the cleavage processing property of HA, which is cleaved by
trypsin treatment. Taken together, our results suggest that the
surface subunit and transmembrane subunit can fold properly
independent of each other and can be efficiently transported to
the cell surface in the context of chimeric proteins. The design
and construction of such chimeric proteins may be applied for
delineating the structural and functional properties of different
domains or subunits of viral glycoproteins.
The design of the HA/gp41 chimeric protein may offer a
new strategy for eliciting antibodies against the gp41 subunit
of the HIV Env protein. The development of HIV vaccines to
elicit cross-reactive neutralizing antibody responses remains a
difficult task for the research community. At least 13 different
vaccines consisting of monomeric HIV-1 Env proteins have
been evaluated in human trials, and were found to induce
antibodies that reacted with gp120, but did not neutralize
primary viral isolates (D'Souza et al., 2000; Montefiori et al.,
2004). One possible reason for the failure of most Env protein
preparations to induce strong neutralizing antibodies may be
attributed to the lack of exposure of neutralizing epitopes for
recognition by the immune system, as indicated by studies of
the structure of the HIV Env protein (Kwong et al., 1998;
Wyatt and Sodroski, 1998). Several studies have found that
the gp41 subunit of the HIV Env protein contains conserved
epitopes that are targets of several broadly neutralizing
antibodies against HIV infection (Muster et al., 1993; Stiegler
et al., 2001; Zwick et al., 2001). However, these epitopes are
not well exposed in the native HIV Env protein. Moreover,
the use of peptides or chimeric proteins containing these
epitopes was not effective in eliciting neutralizing antibodies
against HIV (Coeffier et al., 2000; Eckhart et al., 1996; Liang
et al., 1999; Muster et al., 1995). It has been suggested that
these conserved epitopes may need to be presented in a
membrane-bound oligomeric conformation for eliciting neu-
tralizing antibodies (Ofek et al., 2004; Zwick, 2005).
Therefore, the design of novel antigens that can more
efficiently expose the neutralizing epitopes in gp41 while
maintaining anchorage to the plasma membrane and a pre-
fusion conformation, such as the HA/gp41 chimeric protein
reported here, may lead to the development of AIDS vaccinesthat are more effective in eliciting broadly reactive neutral-
izing antibodies against HIV.
Materials and methods
Cells and reagents
HeLa cells were maintained in DMEM supplemented with
10% fetal calf serum. Monoclonal antibodies against HIV Env
gp41, 2F5, 4E10, 5F3, monoclonal antibody against HIV Env
gp120, 2G12, and polyclonal antibodies against HIV (HIVIG)
were obtained from NIH AIDS Research and Reference
Reagent Program, NIAID, NIH. The monoclonal antibody
NC-1 specific for the six-helix bundle structure of the HIV Env
gp41 has been described in previous studies (Jiang et al., 1998).
Polyclonal antibodies against the HA of influenza virus Aichi
were obtained from rabbits immunized with HA.
Gene construction
The gene fragment encoding the HA1 subunit of influenza
virus A/Aichi/2/68 (H3N2) HA protein was amplified by PCR
using primers GCCACCATGAAGACCATCATTGCT and
ATTGCGCCGAATAGGCCTCGAGTTTGTTTCTCTG,
which introduce a unique XhoI restriction enzyme site at the 3′-
end or the HA1 coding sequence, and then cloned into the
plasmid vector pBlueScript II KS (Strategene) under the control
of the T7 promoter. Subsequently, the coding sequence for the
HIV 89.6 Env gp41 with a truncated cytoplasmic domain (17
amino acids) was amplified by PCR using primers CAA-
ACTCGA GGCATCGGCGCCGTGTTAATGGGC and
TCAAGGCGGGCAGCAGGGTCTGGAA, which introduce a
unique XhoI restriction enzyme site in the 5′-end of the HIV
89.6 gp41 codon-optimized coding sequence, and then cloned
into the HA1 DNA construct at the XhoI site to generate the
gene for the HA/gp41 chimeric protein. Correct linkage of
reading frames was confirmed by sequencing.
Analysis of protein expression by Western blot
Protein expression was carried out using the recombinant
vaccinia virus T7 transient expression system. Briefly, HeLa
cells were seeded in 6-well plate and grown to 90% confluent
overnight. The cells were then infected with recombinant
vaccinia virus VTF7-3, which expresses the T7 polymerase for
2 h followed by transfection with indicated DNA constructs
using Lipofectin (Invitrogen). At 16 h post-infection transfec-
tion, the cells were lysed and cell lysate was added with protein
sample buffer followed by SDS–PAGE. Protein expression was
detected byWestern blot using indicated primary antibodies and
HRP-conjugated secondary antibodies.
For determining cleavage of chimeric proteins by trypsin
treatment, proteins were expressed in HeLa cells using the
vaccinia virus T7 transient expression system. At 16 h post-
infection, the cell were washed twice with PBS and then treated
with trypsin (5 μg/ml in PBS) or PBS at 37 °C for 5 min. The
cells were then lysed and the cell lysate was added with
83L. Ye et al. / Virology 352 (2006) 74–85reducing protein sample buffer. Protein samples were heated at
72 °C for 5 min and then analyzed by SDS–PAGE followed by
Western blot analysis using antibodies against HA or HIV Env
gp41 (2F5), respectively.
Analysis of protein expression by radioactive labeling,
immunoprecipitation, and surface biotinylation
Protein expression was carried out as described above. At
12 h post-infection transfection, cells were starved in Met,
Cys-deficient DMEM for 30 min, and then labeled with 35S-
Met, Cys-labeling mix (Amersham) for 4 h. Surface expression
of HIV Env protein was detected by a surface biotinylation
assay as described in our previous studies (74). Briefly, after
labeling and chase, cells were washed with PBS at 4 °C and
then incubated with 1 ml NHS-SS-Biotin dissolved in PBS
(1 mg/ml) for 30 min at 4 °C. After labeling and surface
biotinylation, the cells were lysed with lysis buffer and then
precipitated with polyclonal antibodies against influenza HA
or HIV (HIVIG) plus protein A–agarose beads (Pierce)
overnight at 4 °C. Proteins bound to protein A agarose beads
were washed three time with lysis buffer and the beads were
added with 10% SDS and heated at 95 °C for 15 min.
Dissociated proteins were precipitated again with streptavidin
agarose beads at 4 °C for 3 h and then washed three times with
lysis buffer. Protein samples were then prepared by addition of
reducing sample buffer, and heated at 95 °C for 5 min prior to
analysis by SDS–PAGE.
To detect protein oligomerization, proteins were expressed as
described above and after radioactive labeling and immunopre-
cipitation, protein samples were prepared by addition of non-
reducing sample buffer and heated at 72 °C for 5 min prior to
analysis by SDS–PAGE in a 3.5% gel. Protein samples prepared
by addition of reducing sample buffer and heated at 95 °C for
5 min were also analyzed by SDS–PAGE in parallel for
comparison.
Surface fluorescence staining and FACS analysis
Protein expression was carried out using the vaccinia virus
T7 transient expression system in T-75 T flasks as described
above. At 16 h post-infection transfection, the cells were
detached from the T flasks by treatment with 2 mM EGTA in
PBS-def (PBS without Ca2+ and Mg2+). The cells were then
washed once with FACS buffer (PBS plus 3% fetal calf serum)
and split into equal aliquots for incubating with each indicated
antibody as specified in the text for 2 h at 4 °C. The cells were
then washed three times with FACS buffer followed by
incubation with appropriate FITC-conjugated secondary anti-
bodies for 1 h at 4 °C, and then washed and fixed with 2%
paraformaldehyde and then analyzed by flow cytometry. Data
were analyzed using the Flowjo 4.2 software.
ELISA
For comparison of reactivity between chimeric proteins
expressed on the cell surface with different antibodies, weemployed a cell surface ELISA assay following established
protocols (Martin et al., 1998). Briefly, protein expression was
carried out in HeLa cells using the vaccinia virus T7 transient
expression system. At 16 h post-infection transfection, the cells
were fixed with 0.5% glutaraldehyde in PBS and then blocked
with PBS plus BSA. The cells were then washed with PBS and
then incubated with indicated primary antibodies for 2 h at room
temperature, followed by wash with PBS and then incubation
with corresponding HRP-conjugated secondary antibodies for
1 h at room temperature. At the end of incubation with
antibodies, the cell were washed and added with substrate TBIS
for development of color. The OD values, which represent the
relative amount of bound primary antibody, were read with an
ELISA reader at the wavelength of 450 nm.
Analysis of protein interaction with antibodies against HA or
the monoclonal antibody NC-1 by ELISAwas carried out using
standard protocols. Protein expression was carried out in HeLa
cells using the vaccinia virus T7 transient expression system as
described above. At 16 h post-infection transfection, cells were
lysed with lysis buffer and cell lysates were used to coat an
ELISA plate. After blocking, indicated primary antibodies were
added, followed by washing and then addition of corresponding
HRP-conjugated secondary antibodies.
DNA immunization and analysis of immune response
Female BALB/c mice (H-2d) 6–8 weeks of age were
purchased from Charles River Laboratory. The gene for the HA/
gp41 chimeric protein was cloned into the plasmid vector
pCAGGS as described previously (Bu et al., 2004; Ye et al.,
2004). Plasmids were amplified in Escherichia coli DH5α and
purified with a Qiagen Endo-Free Megaprep kit and dissolved
in sterile PBS at 1 μg/μl. Mice (groups of 6) were immunized
with a total of 100 μg of indicated DNA construct per mouse by
intra-muscular injection with 50 μl of DNA in separate sites in
both side quadriceps, followed by boosting with the same dose
of DNA at weeks 4 and 8.
Serum samples were collected at 1 week prior to
immunization (pre-immune sera) and 3 weeks after the final
immunization by retro-orbital bleeding, heat-inactivated, and
stored at −80 °C until analysis. Antibody responses against the
HIV gp41 were determined by ELISA as described above
using purified HN/gp41 fusion proteins in which the N-
terminal 72 amino acids of the SV5 HN protein was fused to
the N-terminus of the HIV gp41 protein as coating antigens.
Endpoints were determined as the sample dilutions at which
their absorbance values (OD) are at least 0.05 U above the
mean OD of the group-matched pre-immune sera at the same
dilution.
Sera neutralizing activity was analyzed by single round
infectivity assay as described previously (Bu et al., 2004; Ye et
al., 2004). Briefly, HIV SF162 pseudoviruses were produced by
co-transfection of 293T cells with a DNA construct expressing
the HIV SF162 Env protein and a cDNA construct for Env-
deficient HIV NL-4, tittered in JC53BL cells, and stored at
−80 °C until use. JC53BL cells were seeded at 40,000 cells per
well in a 96-well plate in 10% FCS-DMEM media overnight at
84 L. Ye et al. / Virology 352 (2006) 74–8537 °C with 5% CO2. Serial dilutions of heat-inactivated pooled-
sera from each group were added to pseudovirus stocks diluted
in 10% FCS-DMEM containing 100 infectious particles.
Pseudovirus mixed with group-matched pre-immune sera at
the same dilutions were used as controls. The virus–serum
mixtures were prepared in triplicates and incubated at 37 °C for
1 h and then added to the JC53-BL cells with DEAE-dextran
(final concentration, 15 μg/ml). After 2 h of incubation, an
additional 200 μl of 10% FCS-DMEM was added. Two days
after infection, the medium was removed and the cells were
fixed and stained as described in our previous studies (Vzorov
and Compans, 2000). Neutralization was calculated as (average
number of blue foci in virus–pre-immune serum mixture
control wells − average number of blue foci in virus–serum
mixture sample wells) / (average number of blue foci in virus–
pre-immune serum mixture control wells) × 100%, and
presented as percentage of neutralization.
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